Is MNKD a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Tyvaso DPI royalties, with revenue trend at Q1 2026 total revenue around $90 million, up roughly 15% year over year. The bear case rests on the dominant risk is concentration and dependence on partners and catalysts: a large share of high-margin revenue comes from Tyvaso DPI royalties controlled by United Therapeutics, so any slowdown, competition, or change in that product's trajectory would hit MannKind directly. Analysts covering it are spread from $4.75 to $11.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is concentration and dependence on partners and catalysts: a large share of high-margin revenue comes from Tyvaso DPI royalties controlled by United Therapeutics, so any slowdown, competition, or change in that product's trajectory would hit MannKind directly. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $4.75, +21.8% from the $3.90 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Tyvaso DPI royalties. The most important financial driver is royalty revenue from Tyvaso DPI, which United Therapeutics markets using MannKind's inhalation technology. The most optimistic analyst target on MNKD is $11.00, +182.1% from the $3.90 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is concentration and dependence on partners and catalysts: a large share of high-margin revenue comes from Tyvaso DPI royalties controlled by United Therapeutics, so any slowdown, competition, or change in that product's trajectory would hit MannKind directly. Its owned products, Afrezza and Furoscix, face commercial-execution risk, reimbursement and payer hurdles, and competition, and MannKind has a history of losses, so profitability is not assured. Clinical and regulatory risk is significant: pipeline programs can fail in trials, and FDA decisions can go against the company. As a smaller biopharma, it carries financing risk (it has historically relied on debt and equity), and its shares can be volatile around data and approval events. Broader biotech sentiment and interest rates also affect valuation. The most pessimistic published target is $4.75, +21.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

MannKind Corporation is a biopharmaceutical company built around its proprietary Technosphere dry-powder inhalation platform and, more recently, endocrine and rare-disease products

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Tyvaso DPI royalties) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is concentration and dependence on partners and catalysts: a large share of high-margin revenue comes from Tyvaso DPI royalties controlled by United Therapeutics, so any slowdown, competition, or change in that product's trajectory would hit MannKind directly) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is growing Tyvaso DPI royalties, a fast-ramping Furoscix launch, Afrezza, and a pulmonary pipeline with 2026 catalysts. The bear case is heavy dependence on Tyvaso DPI, a history of losses, and clinical and regulatory risk typical of smaller biopharma. Treat it as a higher-risk, catalyst-driven position.

MannKind is a commercial-stage biopharmaceutical company built around its Technosphere dry-powder inhalation platform and endocrine and rare-disease products. It markets Afrezza inhaled insulin and Furoscix for fluid overload, earns royalties from Tyvaso DPI through a United Therapeutics partnership, and develops a pulmonary pipeline. It makes money from product sales and royalties while investing in clinical programs.

Tyvaso DPI is a dry-powder inhaled therapy that United Therapeutics markets using MannKind's inhalation technology, and the royalties MannKind earns on its sales have become a major, high-margin revenue stream. Because these royalties grow with limited additional cost as the product expands across pulmonary indications, Tyvaso DPI is central to MannKind's earnings and the durability of its cash flow.